News
12d
News-Medical.Net on MSNOwlstone Medical announces investment of up to $2.3 million USD from the Cystic Fibrosis Foundation to develop a breath test for Pseudomonas aeruginosa detectio…Owlstone Medical ("Owlstone"), the global leader in Breath Biopsy ® for applications in early disease detection and precision ...
aeruginosa infection can often receive adequate ... commercially available intravenous products. NA: Not available. Cystic fibrosis (CF) pulmonary disease is characterized by chronic and recurrent ...
11d
MedPage Today on MSNNovel DPP-1 Drug Trims Exacerbation Risk in BronchiectasisThe dipeptidyl peptidase 1 (DPP-1) inhibitor cut the annualized rate of pulmonary exacerbations by around 20% compared with ...
inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa – P.a. or P. aeruginosa – infections in non-cystic fibrosis bronchiectasis, or NCFB, patients.
Cystic fibrosis (CF) is a multisystem ... will be well-informed partners in reducing acquisition of respiratory pathogens, particularly Pseudomonas aeruginosa and Burkholderia cepacia complex.
FRESNO, Calif. (KFSN) -- Cystic Fibrosis is a genetic disorder that affects the lungs, digestive system and other organs. Babies are screened for it when they are born. Now, those living with the ...
The attention motivated Debi and her husband to form a Colorado Springs chapter of the National Cystic Fibrosis Foundation and raise money for the cause. They hosted charity fashion shows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results